about
The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHDA comparison of the effects of reboxetine and placebo on reaction time in adults with Attention Deficit-Hyperactivity Disorder (ADHD)Serum level of semicarbazide-sensitive amine oxidase in children with ADHD.A Review of Pharmacological Management of Attention-Deficit/Hyperactivity DisorderEuropean clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatmentNeuropsychological and neurophysiological benefits from white noise in children with and without ADHDl-Amphetamine improves poor sustained attention while d-amphetamine reduces overactivity and impulsiveness as well as improves sustained attention in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)Impulsiveness, overactivity, and poorer sustained attention improve by chronic treatment with low doses of l-amphetamine in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD).Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV.Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findingsDouble-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder.Efficacy of guanfacine extended release assessed during the morning, afternoon, and evening using a modified Conners' Parent Rating Scale-revised: Short Form.Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropionA randomized, open-label assessment of response to various doses of atomoxetine in korean pediatric outpatients with attention-deficit/hyperactivity disorderIs adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.Drug therapy of attention deficit hyperactivity disorder: current trends.EVENT-RELATED POTENTIAL STUDY OF ATTENTION REGULATION DURING ILLUSORY FIGURE CATEGORIZATION TASK IN ADHD, AUTISM SPECTRUM DISORDER, AND TYPICAL CHILDREN.Osmotic, controlled-release methylphenidate for the treatment of ADHD.Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches.Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study.A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis.Treadmill exercise ameliorates symptoms of attention deficit/hyperactivity disorder through reducing Purkinje cell loss and astrocytic reaction in spontaneous hypertensive ratsPharmacokinetic evaluation of eltoprazine.Metabolic, toxicological, and safety considerations for drugs used to treat ADHD.A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).Aiming for remission in adults with attention-deficit/hyperactivity disorder: The primary care goal.Memantine versus Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial.Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder During Adolescence in the Primary Care Setting: A Concise ReviewGlobal impression of perceived difficulties in children and adolescents with attention-deficit/hyperactivity disorder: reliability and validity of a new instrument assessing perceived difficulties from a patient, parent and physician perspective oveComparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in GermanyEmotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS).Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physiciansAdult ADHD and comorbid disorders: clinical implications of a dimensional approach.Effectiveness of reboxetine in treatment of outpatient children and adolescents with attention deficit-hyperactivity disorder with comorbid anxiety disorders.Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): findings from two 24-week, open-label studies.Perspectives in psychopharmacology: spotlight on atomoxetine.Epitope-tagged receptor knock-in mice reveal that differential desensitization of alpha2-adrenergic responses is because of ligand-selective internalizationPsychostimulants As Cognitive Enhancers in Adolescents: More Risk than Reward?
P2860
Q21203889-E21A1883-448A-498B-9B10-09F522BBD5C5Q21260332-5F25E235-E720-4706-A087-9798F286C861Q24631642-1F8C3746-3830-4F10-B853-E2C260D5E193Q25256999-7E939346-C9BE-45E3-AB17-06D355A7AF50Q26741896-54A734E0-7BE1-4A75-A2EE-B8F9CAD99F94Q28972478-70DF2CA5-EFA2-441C-A7F4-B27817E249C8Q30388254-F607D98B-FA4C-4146-9EFC-511EB0F60496Q30481412-F3C860A2-13BB-4025-8E64-07A70974041BQ30500047-A7DF4F16-8497-4E43-A09B-0591A98FEDA2Q33720856-E47B0E4F-CBFE-41E8-B14E-71874CDC1C9BQ33722315-5D73FDE2-65BA-499F-AE20-867E4D5BA330Q34247801-D5C0A41C-A348-4566-B813-69EC755AA51EQ34371046-531D08FA-E806-4BAF-8A7F-64D54400197CQ35039698-89F7525D-FB94-4804-821C-860887C4EAF7Q35144194-BE394FAE-5228-4061-9E07-6EB4830B13ECQ35896019-59ADDBC5-B933-4F15-A929-2F35DDC0A78FQ35964370-B7948715-7838-4287-9F01-B399C0A1FD38Q36529358-D118BB8C-4BA9-42A8-A297-D215741ADD57Q36613947-9C8F947A-49E0-4F92-B667-FA24E7BFD3E9Q36730671-0E184FEE-90BA-41FE-9A73-B7EC9405E95FQ36838216-EBCC7B09-F8D0-4B3C-844D-450382191B33Q37171395-11AADD76-CAAA-412A-A6B0-3A244195E631Q37542382-00A80CBA-83A5-4800-8B35-8F27BAD4C79BQ37635303-F1C1217F-DDB5-474C-9812-062B58D1F0E6Q37872744-3953E16E-CF74-4247-A0C9-9729287F7CC4Q37993127-4C5A2BFE-E39D-4FF5-9AA6-C7C2FED06477Q38164670-D4A67CCC-E200-4819-8784-7D6BDDF86011Q38348042-903F4D02-11E5-4696-8A6D-B90686CD6E05Q38401702-5FB672DA-BD49-4286-A69F-195CC12A8DCBQ38840904-E52F8A76-B60E-4606-B542-39D7EF1A50F6Q39028113-D24E0513-27E3-4A8F-BD31-37C8411A402EQ39211810-9366DC7E-5ED6-4061-ACA8-E69A63A32956Q39244282-E5E75BC2-1D27-4FE7-8205-11B4D856EACBQ39952803-A7EF8825-E38A-42BF-B860-2C81C59CE566Q41495299-F7750D89-92D4-4AF3-878D-C91074C40DB4Q41515634-4D13C475-C40F-4C8E-8C1D-30D8CADB1C60Q41791034-C82DC9E2-7FE2-4145-9CEC-9BC78FC001B4Q41849467-0D74AD17-1D10-449F-9361-434BC6D21C76Q42092237-00540B4C-A64D-46A0-A1EB-14CEB93075D2Q42369862-5ED9C51D-88EC-4E89-8086-6B80D41868F4
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Non-stimulant medications in the treatment of ADHD.
@ast
Non-stimulant medications in the treatment of ADHD.
@en
type
label
Non-stimulant medications in the treatment of ADHD.
@ast
Non-stimulant medications in the treatment of ADHD.
@en
prefLabel
Non-stimulant medications in the treatment of ADHD.
@ast
Non-stimulant medications in the treatment of ADHD.
@en
P2093
P1476
Non-stimulant medications in the treatment of ADHD.
@en
P2093
Paramala Janardhanan Santosh
Ralf W Dittmann
Veit Roessner
P2888
P304
P356
10.1007/S00787-004-1010-X
P478
13 Suppl 1
P577
2004-01-01T00:00:00Z